When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

Novo Nordisk’s team in India has been pushing the Danish drugmaker’s global leadership for an earlier launch of its popular weight-loss drug Wegovy over ...

Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand ...

Novo Nordisk's team in India is urging the company to launch its popular weight-loss drug, Wegovy, next year to stay ahead of ...

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

We asked our freelance writers to reveal the top US stocks they’d buy in December, which included two Share Advisor 'Fire' ...